SMN Antibody (Rabbit mAb) [C8K16]

CatNo: F8824

    Application: Reactivity:
    • Lane 1: Hela, Lane 2: 293T, Lane 3: K562, Lane 4: U-87 MG
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    転写条件(ウェット): 200 mA, 60 min

    使用情報

    Dilution
    1:1000
    1:30
    1:50
    1:500
    Application
    WB, IP, IF, FCM
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human, Mouse
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    32 kDa 35 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール HeLa cells; Neuro-2a cells; 293T cells; K-562 cells; U-87 MG cells; SH-SY5Y cells
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 60 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    SMN Antibody (Rabbit mAb) [C8K16] detects endogenous levels of total SMN protein.
    タンパク質の局在
    細胞突起、細胞質、細胞核
    Uniprot ID
    Q16637
    Clone
    C8K16
    Synonym(s)
    SMN, SMNT, SMN2, SMNC, SMN1, Survival motor neuron protein, Component of gems 1, Gemin-1
    Background
    Survival motor neuron protein (SMN, also called Gemin 1 in the context of the SMN–Gemin complex) is a ubiquitously expressed RNA-binding protein encoded by the SMN1 and SMN2 genes that forms the structural backbone of a multi-subunit chaperone complex dedicated to the assembly of small nuclear ribonucleoproteins (snRNPs), the core building blocks of the spliceosome. The protein contains a GEMIN2-binding region, a Tudor domain that recognizes symmetrically dimethylated arginine residues on Sm proteins, and a C‑terminal YG box that mediates SMN oligomerization; these domains position SMN at the center of a ring-like SMN complex that includes Gemin2–7 and associated factors and organizes Sm proteins around snRNAs during snRNP biogenesis. In the chaperone-assisted assembly pathway, SMN and Gemin2 accept the preloaded 5Sm complex from the CLNS1A–pICln chaperone, form an intermediate that holds SmD1/D2, SmE/F/G in a position competent for snRNA binding, and then, upon snRNA engagement, are evicted as SmD3 and SmB join to complete the heptameric ring, generating mature core snRNPs that are subsequently modified, imported into the nucleus and incorporated into spliceosomes. SMN localizes both to the cytoplasm and to nuclear gems adjacent to Cajal bodies that are enriched in snRNPs, reflecting its continuous role in snRNP maturation and trafficking in support of pre‑mRNA splicing, including correct splicing of U12-type introns that contribute to normal development of motor and proprioceptive neurons. Beyond snRNP assembly, SMN interacts with a wide range of RNA-binding and RNP proteins (such as hnRNP U/R, GAR1, snoRNP components) and participates in R-loop resolution at transcription termination regions by assisting removal of RNA–DNA hybrids generated by RNA polymerase II, highlighting broader functions in RNA metabolism, transcription termination and possibly telomerase and cytoskeletal regulation. The direct disease relevance of SMN is established by spinal muscular atrophy (SMA), an autosomal recessive motoneuron disease caused by loss-of-function mutations or deletions in SMN1 that reduce full-length SMN protein and lead to widespread splicing defects, with spinal motor neurons particularly vulnerable to reduced snRNP availability and consequent disturbances in neuromuscular junction formation and spinal circuit development. SMN2, a nearly identical centromeric copy of SMN1, modifies disease severity in a dose-dependent manner but predominantly produces transcripts lacking exon 7 due to a single nucleotide change in exon 7 that disrupts splicing; only a minority of SMN2 transcripts are full-length and generate functional SMN, so SMN2 cannot fully compensate for SMN1 loss, although higher SMN2 copy number is associated with milder SMA phenotypes. Developmental regulation of SMN expression shows high levels from SMN1 and SMN2 in early stages followed by progressive decline, suggesting a critical window when reduced SMN drops below threshold and irreversible defects at neuromuscular junctions and spinal circuits occur; this timing underlies therapeutic strategies that upregulate SMN2 splicing to restore SMN before synaptic maturation is compromised.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください